Most men's hormone panels sold direct to consumers report a total testosterone and little else. That number, on its own, cannot tell you whether anything is wrong, and it cannot tell you why. It varies by 20 to 30% between two mornings in the same man, it falls through the day, and it moves with body weight for reasons that have nothing to do with the testes. A panel built around it alone produces a result that feels precise and settles nothing.
Two additions change that. LH and FSH locate the problem, separating a testicular limitation from a pituitary one. SHBG, with albumin, makes free testosterone calculable, which is what matters when the total is being dragged around by carrier protein rather than by production. Everything else on this page exists because the symptoms that send men to order a hormone panel are produced at least as often by thyroid disease, iron deficiency, sleep apnea or insulin resistance as by testosterone.
The Verdict
The hormone panel, and how each marker is read
Ranges below are common adult reference values and vary between laboratories and assay methods. Compare a result against the range printed by the lab that ran it rather than against a number from elsewhere.
| Marker | When to draw it | Typical range | How to read it |
|---|---|---|---|
| Total testosterone | Morning, ideally before 10am, fasting | Roughly 300–1000 ng/dL in adult men, with wide variation between assays | The headline number, and the least informative one in isolation. Intraindividual variation between repeat draws is substantial, which is why guidelines ask for a second confirmatory morning sample before anything is concluded |
| Free testosterone, with SHBG and albumin | Same draw as total | Roughly 5–21 ng/dL by equilibrium dialysis; SHBG roughly 10–57 nmol/L | The fraction available to tissue. Calculated free testosterone needs SHBG and albumin from the same draw, so a panel that omits either cannot produce it |
| LH and FSH | Same draw as total | LH roughly 1.7–8.6 IU/L; FSH roughly 1.5–12.4 IU/L | What separates a testicular problem from a pituitary one. Omitted from most direct-to-consumer panels and the single most decision-changing pair on this list |
| Estradiol, sensitive assay | Same draw as total | Roughly 10–40 pg/mL in men on a mass-spectrometry method | Order the sensitive LC-MS/MS assay explicitly. The standard immunoassay is calibrated for female concentrations and reads unreliably in the male range |
| Prolactin | Morning, avoid after intense exercise or nipple stimulation | Under about 15–20 ng/mL in men | Run it once. An elevated prolactin is a treatable cause of a suppressed axis and points toward imaging rather than replacement |
| DHEA-S | Any day, morning preferred | Peaks in the twenties, falls steadily with age | The adrenal precursor pool. Low values sit behind some low-testosterone pictures and give context the testosterone number alone does not |
The markers that usually change the plan
These are ordinary, widely available tests. They are left off hormone-focused panels precisely because the panel is framed as a hormone question, and they are where a large share of the answers turn out to be.
| Marker group | Target or reference | Why it belongs on this panel |
|---|---|---|
| TSH, free T4, free T3 | TSH roughly 0.4–4.0 mIU/L | Thyroid disease produces fatigue, low libido, low mood and weight change that overlap almost completely with low testosterone. It is cheaper to find and easier to treat |
| CBC with hematocrit, ferritin, transferrin saturation | Hematocrit roughly 41–50%; ferritin above 30 ng/mL as a floor | Hematocrit is the baseline any future therapy is monitored against. High transferrin saturation with a low testosterone and low LH is the screening pattern for hereditary hemochromatosis, which is a diagnosis rather than a deficiency |
| Fasting insulin, HbA1c, fasting glucose | Fasting insulin under about 8 uIU/mL; HbA1c under 5.7% | Insulin resistance lowers SHBG, which lowers total testosterone while free testosterone stays closer to normal. This is one of the most common reasons a total number reads low |
| ApoB, full lipid panel, Lp(a) once | ESC/EAS guideline apoB goals are risk-stratified: under 100 mg/dL at moderate risk, under 80 at high risk, under 65 at very high risk. Lp(a) measured once in a lifetime | The markers that carry the most long-run consequence on the whole panel, and the ones a hormone-focused workup routinely skips. Which target applies depends on your overall risk, which is a calculation rather than a single number |
| hsCRP | Under 1.0 mg/L is low cardiovascular risk; over 3.0 mg/L is high | Interpret only when free of acute illness or injury, both of which raise it substantially |
| PSA, plus a liver panel and creatinine | Standard reference ranges, age-adjusted for PSA | Baseline organ function and a prostate reference point recorded before any treatment decision, because a pre-treatment value cannot be reconstructed later |
| Vitamin D and B12 | Vitamin D commonly targeted at 30–50 ng/mL | Correctable deficiencies that mimic the same symptom cluster |
The cardiovascular group carries the most long-run weight on the page and has the least to do with how anyone feels this week. ApoB counts atherogenic particles rather than measuring their cholesterol cargo, so it can be rising while a standard LDL reading looks unchanged. Lp(a) is genetically set, needs measuring only once, and identifies inherited risk in roughly one in five people that no change in diet or training will move. Neither produces a symptom worth ordering a hormone panel over, and both are more consequential than the hormone results.
What invalidates a result
More hormone panels are undermined by how the sample was collected than by anything the laboratory does with it afterwards.
| What goes wrong | Why it matters | What to do instead |
|---|---|---|
| An afternoon draw | Testosterone follows a daily rhythm that peaks in the early morning. Measured diurnal variation is large enough that an afternoon sample can fall meaningfully below the same man's morning value | Book before 10am and keep the draw time consistent across retests |
| A single low result treated as settled | Biological variation between two mornings is large enough that a substantial share of men with one low value read normal on a repeat draw | Clinical guidelines call for a second confirmatory morning measurement before the result is interpreted |
| Acute illness, injury or recent surgery | Suppresses the whole axis temporarily and raises hsCRP | Wait until recovered rather than testing through it |
| A hard training session or a poor night's sleep before the draw | Restricting sleep to about 5 hours a night for a week lowered daytime testosterone by 10–15% in healthy young men in a controlled trial published in JAMA | Test after a normal week, not after a deload, a race, or a run of short nights |
| High-dose biotin supplements | Interferes with many immunoassays and can shift hormone and thyroid results in either direction | Laboratories commonly advise a 48–72 hour biotin washout before a draw. Worth raising with whoever ordered the test |
| A standard estradiol immunoassay | Not reliable at male concentrations, so the result is noise rather than a low or high reading | Specify the sensitive LC-MS/MS method on the requisition |
| Opioids, glucocorticoids or anabolic steroid use | All suppress the axis directly, and exogenous testosterone drives LH and FSH toward undetectable | Disclose them, because the panel reads as secondary hypogonadism either way and the cause is already known |
Reading the panel in combination
Single values rarely decide anything here. Combinations do, and the six below are the ones that most often redirect a plan.
| Pattern | What it usually reflects | What follows from it |
|---|---|---|
| Low testosterone with high LH and FSH | Primary hypogonadism, meaning the testes are the limiting step | The pituitary is signalling normally and the response is absent. This is the picture that most often leads to a replacement conversation |
| Low testosterone with low or inappropriately normal LH and FSH | Secondary hypogonadism, meaning the signal from the pituitary or hypothalamus is the limiting step | Prompts a search for a cause: prolactin, iron studies, medication review, and imaging if a clinician judges it warranted. Several causes here are reversible |
| Low total testosterone, low SHBG, normal free testosterone | An SHBG effect rather than a testosterone deficiency, most often driven by insulin resistance or excess weight | The total number is misleading in this pattern. Free testosterone and the metabolic panel are what to read |
| Low testosterone with a high transferrin saturation | Possible hereditary hemochromatosis affecting the pituitary | Iron overload is a diagnosis with its own treatment. Finding it changes the plan entirely |
| Normal testosterone with the full symptom picture | Something other than the hormone axis | Sleep apnea, thyroid disease, iron deficiency, depression and alcohol all produce this presentation and all have specific treatments |
| Rising hematocrit above roughly 54% during therapy | Erythrocytosis, the most common measurable adverse effect of testosterone therapy | A monitoring threshold that prompts a clinician review of dose and route |
One pattern deserves separating out. Fatigue, low libido, low mood and difficulty holding lean mass, presenting alongside entirely normal hormone values, is common on this panel. Obstructive sleep apnea is the most under-recognised explanation, and it runs in both directions, since untreated apnea also lowers testosterone. Iron deficiency, subclinical thyroid disease, depression, heavy alcohol use and chronic short sleep produce the same picture. Treating the panel as a hormone question by default is how those get missed for a year.
What to do with the results
- Confirm before concluding. A second morning measurement is the step most likely to change the interpretation, and it costs one more draw.
- Read the pattern, not the headline number. Total testosterone in isolation is the least informative value on the requisition.
- The non-hormonal findings are common alternative explanations. Thyroid disease, iron deficiency, vitamin D deficiency, short sleep and heavy alcohol use produce much of the same symptom cluster, and clinicians generally work through them before attributing symptoms to the hormone axis.
- Take a secondary picture to a clinician for a cause. Low testosterone with low LH and FSH warrants a search rather than a substitution.
- ApoB and Lp(a) run on their own timeline. They are risk markers rather than symptoms, the relevant window is measured in decades, and Lp(a) in particular is genetically set rather than something lifestyle moves.
- Retest what trends, not what fluctuates. ApoB, fasting insulin, HbA1c, ferritin, hematocrit and thyroid annually. Repeat hormones when a specific decision depends on them.
The two-morning confirmation rule, the reference thresholds and the monitoring parameters described above come from published clinical guidance rather than from this site. The Endocrine Society clinical practice guideline on testosterone therapy and the American Urological Association guideline on testosterone deficiency are both readable in full and are the documents a clinician is most likely to be working from.
Testosterone therapy is a prescription decision with real contraindications and a monitoring schedule attached, including hematocrit and PSA surveillance, and it suppresses fertility in a way that matters to anyone considering children. Those are conversations for a clinician who has your history and your results in front of them, not conclusions to be drawn from a panel. See one promptly for breast tissue changes, visual field changes or headaches alongside a high prolactin, testicular changes, or symptoms severe enough to disrupt work and sleep.
Frequently Asked Questions
What blood tests belong on a men's hormone panel?
Hormones: total testosterone, free testosterone with SHBG and albumin, LH and FSH, a sensitive estradiol assay, prolactin once, and DHEA-S. Beyond the hormones, where a large share of the actionable findings sit: a full thyroid panel, CBC with hematocrit, ferritin and transferrin saturation, fasting insulin and HbA1c, ApoB with a one-time Lp(a), hsCRP, a baseline PSA, liver and kidney function, vitamin D and B12. A standard annual physical covers a fraction of that list, and most direct-to-consumer hormone panels cover the first line and stop.
Why does the draw have to be in the morning?
Testosterone follows a daily rhythm that peaks in the early morning and declines through the day. The amplitude is blunted with age but does not disappear, so an afternoon sample can read roughly 20–25% below the same man's 8am value. That is large enough to move a result across a diagnostic threshold on timing alone. Draw before 10am, fasting where practical, and keep the time consistent between tests so that a change reflects biology rather than scheduling.
Why do guidelines want the test repeated?
Because a single measurement is noisy. Day-to-day biological variation, assay variation and the daily rhythm combine so that a meaningful proportion of men with one low reading return a normal value on a second morning draw. Endocrine Society and urology guidance both call for two separate morning measurements before low testosterone is considered established. A programme that starts treatment from one number has skipped the step most likely to change the answer.
My testosterone came back borderline. What happens next?
Borderline is the most common result and the least useful one, because a value near the threshold is exactly where measurement noise decides which side of the line it lands on. In practice a clinician repeats it as a second early-morning fasting sample rather than acting on the first, and reads it alongside LH, FSH and SHBG rather than alone, since a borderline total with a low SHBG and a normal free testosterone points somewhere different from a borderline total with a high LH. Symptoms carry weight here too: guidelines frame the diagnosis as consistent symptoms plus unequivocally low measurements, not a number in isolation. If both draws sit near the threshold and the symptoms are mild, watchful repeat testing some months later is a normal path rather than a failure to decide.
Should estradiol be on a men's panel at all?
Yes, with the right assay. Estradiol in men comes largely from aromatisation of testosterone in fat tissue, and it matters for bone density, libido and body composition rather than being something to drive as low as possible. The practical issue is measurement: the standard immunoassay most labs run by default is calibrated for female concentrations and performs poorly at the much lower male range, so it produces a number that should not be acted on. Ask for the sensitive liquid chromatography mass spectrometry method by name.
Can excess weight explain a low testosterone result?
It frequently does, through two mechanisms at once. Adipose tissue aromatises testosterone to estradiol, and insulin resistance suppresses SHBG, the carrier protein most of circulating testosterone is bound to. Lower SHBG mechanically lowers the total testosterone number while free testosterone stays closer to normal. That is why the pattern of a low total, a low SHBG and a normal free testosterone points toward metabolic health rather than toward a deficiency of the hormone itself, and why fasting insulin belongs on the same requisition.
How often should the panel be repeated?
For a baseline with no therapy under way, an annual repeat of the hormones is enough unless something specific changes. The markers worth tracking on a schedule are the ones that trend rather than fluctuate: ApoB, fasting insulin, HbA1c, ferritin, hematocrit and thyroid function. Lp(a) is measured once in a lifetime. If a clinician starts therapy, the monitoring cadence is theirs to set and typically involves rechecking testosterone, hematocrit and PSA within the first several months and then periodically.
What does a full panel cost?
Ordered through insurance with documented symptoms, much of it is covered, since thyroid, CBC, ferritin, lipids, glucose and HbA1c are routine. Self-pay, a broad panel including the hormone and advanced cardiovascular markers typically runs $150 to $400 at direct-to-consumer labs. Physician-led programmes that bundle the panel with consultations and retesting generally run $150 to $400 a month before any medication, which is a different purchase from the labs themselves. The doctor-led options page lays out how those programmes differ from ordering the labs directly.
Related
- Free vs total testosterone: why the two numbers disagree and which one to read
- Signs of low testosterone: the symptom picture and what else produces it
- SHBG: the carrier protein that moves the total testosterone number
- Fasting insulin: insulin resistance appears years before glucose moves
- ApoB: the cardiovascular marker that outranks the hormones for consequence
- Normal vs optimal ranges: why a reference range is not a target